Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
FMX103 minocycline foam 1.5%
VYNE Therapeutics
Facial Papulopustular Rosacea
2 trials -
FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM
Tour Hekla
Benign Prostate Hyperplasia
1 trial -
FUROSEMIDE , DULOXETINE
Ningbo Cancer Hospital
ER positive HER2 negative breast cancer stages I-II
1 trial -
FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, HYDROCHLOROTHIAZIDE
The George Institute
Acute Heart Failure
1 trial -
FX006
Pacira Ireland Limited
Osteoarthritis of the Knee
2 trials -
FX006 32 mg
Pacira Ireland Limited
Osteoarthritis of the Knee
4 trials -
Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.
Sanofi-aventis Healthcare Pty Ltd
Fabryβs disease
1 trial -
Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Takeda
Hemophilia A or B With Inhibitors
1 trial -
Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)
Baxalta Innovations GmbH
Hemophilia A or B With Inhibitors
1 trial -
Faricimab
Hoffmann-La Roche
Diabetic Macular Edema
1 trial -
Farletuzumab
United Therapeutics Europe Ltd
Ovarian Cancer
1 trial -
Fasedienol Nasal Spray
Vistagen Therapeutics
Social Anxiety Disorder
1 trial -
Fasedienol Nasal Spray
Vistagen Therapeutics
Social Anxiety Disorder (SAD)
1 trial -
Fasinumab
Regeneron UK Limited
Osteoarthritis of the Knee or Hip
1 trial -
Femara 2.5 mg film-coated tablets, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Anastrozole 1mg film-coated tablets, Docetaxel Pfizer 10 mg/mL concentrate for solution for infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Exemestane 25 mg Film-coated Tablets, Carboplatin 10 mg/ml Concentrate for Solution for Infusion, Abraxane 5 mg/ml powder for dispersion for infusion.
Ningbo Cancer Hospital
low-grade serous carcinoma of the ovary or peritoneum
1 trial -
Fezolinetant
Astellas Pharma Inc
Hot Flashes
1 trial -
Ficerafusp alfa
Bicara Therapeutics
Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Crohn's Disease
2 trials -
Filgotinib
Lakefront Biotherapeutics NV
Ulcerative Colitis
2 trials -
Filgotinib
Lakefront Biotherapeutics NV
Psoriatic Arthritis
4 trials -
Filgotinib
Lakefront Biotherapeutics NV
Ankylosing Spondylitis
3 trials -
Finerenone (BAY94-8862)
Bayer HealthCare AG
Chronic Kidney Disease
1 trial -
Finerenone (BAY94-8862)
Bayer HealthCare AG
Diabetic Kidney Disease
1 trial -
Finerenone (BAY94-8862)
Bayer HealthCare AG
Heart Failure
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources